Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Income from Non-Controlling Interests (2022 - 2025)

MoonLake Immunotherapeutics' Income from Non-Controlling Interests history spans 4 years, with the latest figure at -$591000.0 for Q4 2025.

  • Quarterly Income from Non-Controlling Interests rose 21.41% to -$591000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.4 million through Mar 2026, up 7.0% year-over-year, with the annual reading at -$3.0 million for FY2025, 32.76% down from the prior year.
  • Income from Non-Controlling Interests came in at -$591000.0 for Q4 2025, up from -$969000.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $588195.0 in Q4 2022 to a low of -$5.3 million in Q2 2022.
  • The 4-year median for Income from Non-Controlling Interests is -$831000.0 (2025), against an average of -$1.6 million.
  • Year-over-year, Income from Non-Controlling Interests tumbled 270.59% in 2023 and then skyrocketed 90.6% in 2024.
  • MoonLake Immunotherapeutics' Income from Non-Controlling Interests stood at $588195.0 in 2022, then crashed by 270.59% to -$1.0 million in 2023, then increased by 25.06% to -$752000.0 in 2024, then grew by 21.41% to -$591000.0 in 2025.
  • Per Business Quant, the three most recent readings for MLTX's Income from Non-Controlling Interests are -$591000.0 (Q4 2025), -$969000.0 (Q3 2025), and -$831000.0 (Q2 2025).